Background: Procalcitonin (PCT) is being used as a marker of bacterial infections. Although there are several studies showing the diagnostic yield of PCT to differentiate bacterial involvement in chronic obstructive pulmonary disease exacerbations (COPDE), the prognostic yield of PCT in severe COPDE has been studied less. Objectives: The primary aim was to determine whether the level of serum PCT at admission in severe COPDE serves as a prognostic biomarker for hospital mortality. The secondary aim was to determine the role of PCT in identifying a bacterial exacerbation. Methods: A total of 63 COPDE patients (median age 71 years; male 58.7%) were retrospectively analyzed from our intensive care unit database. Results: The hospital mortality rate was 23.8%. Admission PCT levels were higher in patients who died during hospitalization (0.66 vs. 0.17 ng/ml; p = 0.014). This association between hospital mortality and serum PCT level remained significant in a multivariate analysis; for every 1 ng/ml increase in PCT level, hospital mortality increased 1.85 times (odds ratio; 95% confidence interval: 1.07-3.19; p = 0.026). The optimal admission PCT threshold was 0.25 ng/ml in order to discern patients who had bacterial exacerbation with a sensitivity of 63%, a specificity of 67%, and a negative predictive value of 80%. The negative predictive value increased to 89% when both the admission and follow-up PCT levels remained <0.25 ng/ml. Conclusion: This study shows that admission PCT levels have a prognostic importance in estimating hospital mortality among patients with severe COPDE. A PCT level <0.25 ng/ml at the time of admission and during follow-up is suggestive of the absence of a bacterial cause of COPDE.

1.
NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2015). http://www.goldcopd.com.
2.
Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
3.
Miravitlles M, Murio C, Guerrero T, Gisbert R; DAFNE Study Group: Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-1455.
4.
Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA: Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT Investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-967.
5.
Wedzicha JA, Seemungal TA: COPD exacerbations: defining their cause and prevention. Lancet 2007;370:789-796.
6.
White AJ, Gompertz S, Stockley RA: Chronic obstructive pulmonary disease. 6. The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003;58:73-80.
7.
Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, Murphy TF: Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:356-361.
8.
Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.
9.
Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
10.
Stolz D, Tamm M: Discriminate use of antibiotics for exacerbation of COPD. Curr Opin Pulm Med 2000;15:126-132.
11.
Miravittles M: Do we need antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis 2007;1:61-76.
12.
Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA: Antibiotics for exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;12:CD010257.
13.
Gotfried M, Busman TA, Norris S, Notario GF: Role of 5-day, once-daily extended release clarithromycin in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin 2007;23:459-466.
14.
Tang BM, Eslick GD, Craig JC, McLean AS: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-217.
15.
Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B: Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006;32:469-472.
16.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized single-blinded intervention trial. Lancet 2004;363:600-607.
17.
Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wobers M, Widmer I, Niedert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B; ProHOSP Study Group: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-1066.
18.
Christ-Crain M, Müller B: Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556-573.
19.
Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M: Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin guidance with standard therapy. Chest 2007;131:9-19.
20.
Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, Ruggieri V, Plebani M, Barbaro MP, Spanevello A, Canonica GW, Papi A, Fabbri LM, Beghe B; FARM58J2XH Study Group: Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One 2015;10:e0118241.
21.
Daubin C, Parienti JJ, Vabret A, Ramakers M, Fradin S, Terzi N, Freymuth F, Charbonneau P, du Cheyron D: Procalcitonin levels in acute exacerbation of COPD admitted to ICU: a prospective cohort study. BMC Infect Dis 2008;8:145-153.
22.
Rammaert B, Verdier N, Cavestri B, Nseir S: Procalcitonin as a prognostic factor in severe exacerbations of chronic obstructive pulmonary disease. Respirology 2009;14:969-974.
23.
Horie M, Ugajin M, Suzuki M, Noguchi S, Tanaka W, Yoshihara H, Kawakami M, Kichikawa Y, Sakamoto Y: Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia. Am J Med Sci 2012;343:30-35.
24.
Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G, Rivers E, Balk RA, Laterre PF, Angus DC, Reinhart K, Brunkhorst FM: Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011;15:R88.
25.
Liu D, Su L, Han G, Yan P, Xie L: Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS One 2015;10:e0129450.
26.
Kenzaka T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, Kitao A, Kajii E, Hashimoto M: Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis. Int J Gen Med 2012;5:483-488.
27.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
28.
Bafadhel M, Clark TW, Reid C, Medina MJ, Bathan S, Barer MR, Nicholson KG, Brightling CE: Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011;139:1410-1418.
29.
Berg P, Lindhardt BO: The role of procalcitonin in adult patients with community- acquired pneumonia. Dan Med J 2012:59:A4353.
30.
Giamarellos-Bourboulis EJ, Mega A, Grecka P, Scarpa N, Koratzanis G, Thomopoulos G, Giamarellou H: Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 2002;28:1351-1356.
31.
Ramírez P, Ferrer M, Martí V, Reyes S, Martínez R, Menéndez R, Ewig S, Torres A: Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011;39:2211-2217.
32.
Kibe S, Adams K, Barlow G: Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011;66(suppl 2):ii33-ii40.
33.
Hillas G, Vassilakopoulos T, Plantza P, Rasidakis A, Bakakos P: C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 2010;35:805-811.
34.
Kutz A, Briel M, Christ-Crain M, Stolz D, Boudma L, Wolff M, Kristoffersen KB, Wei L, Burkhardt O, Welte T, Schroeder S, Nobre V, Tamm M, Bhatnagar N, Bucher HC, Luyt CE, Chastre J, Tubach F, Mueller B, Schuetz P: Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Crit Care 2015;19:74-85.
35.
Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E: Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013;17:R115.
36.
Mat Nor MB, Md Ralib A: Procalcitonin clearance for early prediction of survival in critically ill patients with severe sepsis. Crit Care Res Pract 2014;2014:819034.
37.
Luyt CE, Guerin V, Combes A, Trouillet JL, Ayed SB, Bernard M, Gibert C, Chastre J: Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005;171:48-53.
38.
Tanriverdi H, Tor MM, Kart L, Altın R, Atalay F, Sümbüloğlu V: Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator associated pneumonia. Ann Thorac Med 2015;10:137-142.
39.
Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40-46.
40.
Sethi S, Murphy TF: Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001;14:336-363.
41.
Miravitlles M: Is it possible to reduce the use of antibiotics in severe exacerbations of chronic obstructive pulmonary disease? Respiration 2008;76:249-250.
42.
Stolz D, Tamm M: Discriminate use of antibiotics for exacerbation of COPD. Curr Opin Pulm Med 2009;15:126-132.
43.
Schuetz P, Albrich W, Mueller B: Procalcitonin for diagnosis of infections and guide to antibiotic decisions: past, present and future. BMC Med 2011;9:107.
44.
Nseir S, Cavestri B, Di Pompeo C, Diarra M, Brisson H, Lemyze M, Roussel-Delvallez M, Durocher A: Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008;76:253-260.
45.
Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, Boersma WG: Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010;138:1108-1115.
46.
Schuetz P, Suter Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B; Procalcitonin-Guided Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group: Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011;37:384-392.
47.
Confalonieri M, Garuti G, Cattaruzza MS, Osborn JF, Antonelli M, Conti G, Kodric M, Resta O, Marchese S, Gregoretti C, Rossi A; Italian Noninvasive Positive Pressure Ventilation (NPPV) Study Group: A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation. Eur Respir J 2005;25:348-355.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.